Overexpression of ubiquitin-specific protease 2a (USP2a) and nuclear factor erythroid 2-related factor 2 (Nrf2) in

Mohammad Reza Boustani1, Reza Jalili Khoshnood2, Fermoozan Nikpasand3

  • 1Department of Neurosurgery, AJA University of Medical Sciences, Tehran, Iran.

Abstract

Insights

High expression of USP2a and Nrf2 correlates with poor prognosis in glioma patients. These proteins may serve as valuable prognostic markers for glioma, aiding in patient outcome prediction.

Area of Science:

  • Neuro-oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Gliomas represent a significant portion of adult primary brain tumors.
  • Targeting glioma cell differentiation and self-renewal offers novel therapeutic avenues.

Purpose of the Study:

  • To evaluate USP2a (Ubiquitin-specific protease 2a) and Nrf2 (Nuclear factor erythroid 2-related factor 2) expression in glioma patients.
  • To determine the association of USP2a and Nrf2 expression with glioma prognosis.

Main Methods:

  • Immunohistochemical staining was performed on 40 primary glioma tissue samples.
  • USP2a and Nrf2 expression levels were analyzed.
  • Statistical analysis included SPSS, X(2) test, log-rank test, and Kaplan-Meier survival analysis.

Main Results:

  • USP2a and Nrf2 expression were significantly elevated in glioma tissues compared to normal brain tissues.
  • Increased USP2a and Nrf2 expression correlated with advanced tumor grade and age.
  • High USP2a expression was associated with shorter overall survival, while high Nrf2 expression was linked to poorer survival.
  • Both USP2a and Nrf2 were identified as independent predictors of overall survival in multivariate analysis.

Conclusions:

  • USP2a and Nrf2 expression levels show potential as prognostic markers in glioma patients.
  • These findings may contribute to improved patient stratification and treatment strategies for gliomas.